Insights from molecular dynamics simulations for computational protein design
MC Childers, V Daggett - Molecular systems design & engineering, 2017 - pubs.rsc.org
A grand challenge in the field of structural biology is to design and engineer proteins that
exhibit targeted functions. Although much success on this front has been achieved, design …
exhibit targeted functions. Although much success on this front has been achieved, design …
Rationally designed peptides and peptidomimetics as inhibitors of amyloid-β (Aβ) aggregation: Potential therapeutics of Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease with no clinically
accepted treatment to cure or halt its progression. The worldwide effort to develop peptide …
accepted treatment to cure or halt its progression. The worldwide effort to develop peptide …
SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers
D Shea, E Colasurdo, A Smith… - Proceedings of the …, 2022 - National Acad Sciences
The formation of toxic Amyloid β-peptide (Aβ) oligomers is one of the earliest events in the
molecular pathology of Alzheimer's Disease (AD). These oligomers lead to a variety of …
molecular pathology of Alzheimer's Disease (AD). These oligomers lead to a variety of …
α-Sheet secondary structure in amyloid β-peptide drives aggregation and toxicity in Alzheimer's disease
Alzheimer's disease (AD) is characterized by the deposition of β-sheet–rich, insoluble
amyloid β-peptide (Aβ) plaques; however, plaque burden is not correlated with cognitive …
amyloid β-peptide (Aβ) plaques; however, plaque burden is not correlated with cognitive …
Peptide‐based molecular strategies to interfere with protein misfolding, aggregation, and cell degeneration
V Armiento, A Spanopoulou… - Angewandte Chemie …, 2020 - Wiley Online Library
Protein misfolding into amyloid fibrils is linked to more than 40 as yet incurable cell‐and
neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and type 2 …
neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and type 2 …
Peptides, peptidomimetics, and carbohydrate–peptide conjugates as amyloidogenic aggregation inhibitors for Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder accounting for 60–
80% of dementia cases. For many years, AD causality was attributed to amyloid-β (Aβ) …
80% of dementia cases. For many years, AD causality was attributed to amyloid-β (Aβ) …
Amyloid-β oligomers: multiple moving targets
D Shea, V Daggett - Biophysica, 2022 - mdpi.com
Alzheimer's Disease (AD) is a neurodegenerative disorder that is characterized clinically by
progressive cognitive decline and pathologically by the β-sheet rich fibril plaque deposition …
progressive cognitive decline and pathologically by the β-sheet rich fibril plaque deposition …
Antimicrobial α-defensins as multi-target inhibitors against amyloid formation and microbial infection
Amyloid aggregation and microbial infection are considered as pathological risk factors for
developing amyloid diseases, including Alzheimer's disease (AD), type II diabetes (T2D) …
developing amyloid diseases, including Alzheimer's disease (AD), type II diabetes (T2D) …
The role of α-sheet structure in amyloidogenesis: Characterization and implications
T Prosswimmer, V Daggett - Open Biology, 2022 - royalsocietypublishing.org
Amyloid diseases are linked to protein misfolding whereby the amyloidogenic protein
undergoes a conformational change, aggregates and eventually forms amyloid fibrils. While …
undergoes a conformational change, aggregates and eventually forms amyloid fibrils. While …
Use of peptides for the management of Alzheimer's disease: diagnosis and inhibition
Alzheimer's disease (AD) is a form of dementia and the most common progressive
neurodegenerative disease (ND). The targeting of amyloid-beta (Aβ) aggregation is one of …
neurodegenerative disease (ND). The targeting of amyloid-beta (Aβ) aggregation is one of …